Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00288262 · ClinicalTrials.gov registry record · Phase 1

Melatonin Effects on Luteinizing Hormone

A Phase 1 study, sponsored by Scripps Health.

Terminated
Registry status
Phase 1
Development phase
20
Enrollment target

NCT00288262 is a Phase 1 study that was terminated before completion, run by Scripps Health. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00288262, a Phase 1 study, was terminated before completion, sponsored by Scripps Health.

TERMINATED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

In many mammals, the duration of the nocturnal melatonin elevation regulates seasonal changes in reproductive hormones such as luteinizing hormone (LH). Melatonin's effects on human reproductive endocrinology are uncertain. It is thought that the same hypothalamic pulse generator may both trigger the pulsatile release of GnRH and LH and also cause hot flashes. Thus, if melatonin suppressed this pulse generator in postmenopausal women, it might moderate hot flashes. This clinical trial tested the hypothesis that melatonin could suppress LH and relieve hot flashes.

Interventions

  • DRUG melatonin 0.5 mg

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2004-06
Est. Completion 2005-02
Phase Phase 1

Sponsor

Scripps Health

30 total trials

What the Registry Record Tells You About NCT00288262

The ClinicalTrials.gov registry entry for NCT00288262 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scripps Health, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which melatonin 0.5 mg is the first listed.

NCT00288262 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00288262 about?

NCT00288262 is a clinical study titled "Melatonin Effects on Luteinizing Hormone". In many mammals, the duration of the nocturnal melatonin elevation regulates seasonal changes in reproductive hormones such as luteinizing hormone (LH). Melatonin's effects on human reproductive endocrinology are uncertain. It is thought that the same hypothalamic pulse generator may both trigger th...

What is the current status of trial NCT00288262?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2004-06. Estimated completion is 2005-02.

What interventions are being tested in trial NCT00288262?

The interventions under investigation include: melatonin 0.5 mg (DRUG).

Who is sponsoring clinical trial NCT00288262?

This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.